Bristol-Myers Squibb Stock: Zenbexus with FDA Approval

{
  "signal_id": "1ce0159c-bd09-fce0-37f1-3ba6ae0326a4",
  "signal_type": "news",
  "signal_subtype": "partners_with",
  "detected_at": "2026-08-23T08:53:04+00:00",
  "company": {
    "name": "Bristol Myers Squibb",
    "domain": "bms.com"
  },
  "data": {
    "url": "https://www.ad-hoc-news.de/boerse/news/unternehmensnachrichten/bristol-myers-squibb-aktie-zenbexus-mit-fda-zulassung/69988992",
    "title": "Bristol-Myers Squibb Stock: Zenbexus with FDA Approval - Ad-hoc-news.de",
    "excerpt": "Bristol-Myers Squibb combines technological upgrades with medical advancements to solidify its position in the oncology market. Following a significant regulatory breakthrough, the pharmaceutical group announced a collaboration in the field of Artificial Intelligence to accelerate the development of new antibodies. Investors reacted positively to the latest operational progress on the stock market, with the stock closing at 57.51 Euros on Friday.\nAs the company announced, Bristol-Myers Squibb will collaborate with Chai Discovery in the future. The goal of this partnership is to use AI-powered models for the discovery and optimization of biological drug candidates. The system utilizes molecular folding models and is intended to serve as a continuously learning platform to more efficiently address complex target structures in drug research. The cooperation is part of a broader strategy to secure its own biologics pipeline through technological innovations.\nA key milestone for short-term revenue development is the accelerated approval of Zenbexus by the US Food and Drug Administration (FDA) on August 13. The combination therapy is used for adult patients with multiple myeloma who have already received at least one prior treatment. In the underlying Phase 3 study EXCALIBER-RRMM, the therapy showed an MRD-negative response rate (minimal residual disease) of 41 percent, while the...",
    "summary": "Bristol-Myers Squibb is partnering with Chai Discovery to use AI-powered models for the discovery and optimization of biological drug candidates.",
    "planning": true,
    "image_url": "https://mdb.ad-hoc-news.de/bild/bild-2773592_1920_1080.webp",
    "confidence": 0.9,
    "published_at": "2026-08-23T08:53:04Z",
    "article_sentence": "As the company announced, Bristol-Myers Squibb will collaborate with Chai Discovery in the future.",
    "related_company_name": "Chai Discovery",
    "related_company_domain": "chaidiscovery.com"
  }
}

curl https://signals.autobound.ai/v1/signals/1ce0159c-bd09-fce0-37f1-3ba6ae0326a4 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"bms.com","limit":20}'